Interpace Biosciences (OTCQX: IDXG) is a leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. Interpace Diagnostics is a fully integrated commercial and bioinformatics business unit that provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace Pharma Solutions provides pharmacogenomics testing, genotyping, biorepository and other customized services to the pharmaceutical and biotech industries and advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, and improving patient care.
| Website | http://interpace.com |
| Revenue | $20.9 million |
| Employees | 117 (70 on RocketReach) |
| Phone | +1 215-525-5207 |
| Industry | Biotechnology Research |
| Competitors | Natera, Exact Sciences, Guardant Health, Myriad Genetics, Foundation Medicine, Invitae, Biodesix, Inc., Clarify Health Solutions, Genomic Health, PAML +27 more (view full list) |
Looking for a particular Interpace Biosciences employee's phone or email?
The Interpace Biosciences annual revenue was $20.9 million in 2026.
Tom Burnell is the President and CEO of Interpace Biosciences.
70 people are employed at Interpace Biosciences.